Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard A Burris

Showing results (151-160 of 247) with videos related to

Pageof 25
Sort By:
Clinical Lung Cancer|October 10, 2007
Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research NetworkF Anthony Greco, David R Spigel, Michel E Kuzur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2009
A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumorsRoger B Cohen, Suzanne F Jones, Charu Aggarwal, et al.
European Journal of Clinical Pharmacology|August 31, 2013
Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumorsHuali Wu, Jeffrey R Infante, Vicki L Keedy, et al.
Cancer Discovery|December 8, 2021
Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket StudyClaire F Friedman, John D Hainsworth, Razelle Kurzrock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancerDavid R Spigel, Howard A Burris, F Anthony Greco, et al.
The Oncologist|December 15, 2010
Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumorsAntoinette R Tan, Afshin Dowlati, Suzanne F Jones, et al.
Cancer Chemotherapy and Pharmacology|January 25, 2012
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancerSandhya Girish, Manish Gupta, Bei Wang, et al.
Investigational New Drugs|November 27, 2012
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumorsJeffrey R Infante, Silvia Novello, Wen Wee Ma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumorsJeffrey R Infante, D Ross Camidge, Linda R Mileshkin, et al.
Lung Cancer (Amsterdam, Netherlands)|September 6, 2012
Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancerDavid R Spigel, F Anthony Greco, David M Waterhouse, et al.
Pageof 25

Showing results (151-160 of 247) with videos related to

Sort By:
Pageof 25
Clinical Lung Cancer|October 10, 2007
Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research NetworkF Anthony Greco, David R Spigel, Michel E Kuzur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2009
A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumorsRoger B Cohen, Suzanne F Jones, Charu Aggarwal, et al.
European Journal of Clinical Pharmacology|August 31, 2013
Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumorsHuali Wu, Jeffrey R Infante, Vicki L Keedy, et al.
Cancer Discovery|December 8, 2021
Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket StudyClaire F Friedman, John D Hainsworth, Razelle Kurzrock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancerDavid R Spigel, Howard A Burris, F Anthony Greco, et al.
The Oncologist|December 15, 2010
Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumorsAntoinette R Tan, Afshin Dowlati, Suzanne F Jones, et al.
Cancer Chemotherapy and Pharmacology|January 25, 2012
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancerSandhya Girish, Manish Gupta, Bei Wang, et al.
Investigational New Drugs|November 27, 2012
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumorsJeffrey R Infante, Silvia Novello, Wen Wee Ma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumorsJeffrey R Infante, D Ross Camidge, Linda R Mileshkin, et al.
Lung Cancer (Amsterdam, Netherlands)|September 6, 2012
Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancerDavid R Spigel, F Anthony Greco, David M Waterhouse, et al.
Pageof 25